CytomX Therapeutics $100 million follow-on offering
We advised the joint book-running managers in connection with the equity offering
1/25/2021

Davis Polk advised the joint book-running managers in connection with a $100 million public offering of common stock by CytomX Therapeutics, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “CTMX.”

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow and Ganiatu Afolabi. The tax team included partner Michael Farber and associate Sunny Kim. Partner David R. Bauer and associate Christopher C. Woller provided intellectual property advice. Associate Allison Gunther provided ‘40 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.